AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18936596 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib 20 mg once daily
Number of subjects: 0
Study 18936596 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib 20 mg twice daily
Number of subjects: 0
Study 18936596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15619066 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular interventions
Number of subjects: 0
Study 15619066 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular surgery
Number of subjects: 0
Study 15619066 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery of a ruptured aneurysm
Number of subjects: 0
Study 15619066 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid, aneurysm, and bypass surgery
Number of subjects: 0
Study 14716525 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-free diet
Number of subjects: 176
Study 14716525 — intervention group
Group type: COMPARATOR
Intervention: Unrestricted diet
Number of subjects: 176
Study 10516516 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic exercise with the Cybex 6000 dynamometer
Number of subjects: 67
Study 10516516 — intervention group
Group type: COMPARATOR
Intervention: Isometric exercise with the Cybex 6000 dynamometer
Number of subjects: 67
Study 8684198 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline 0.1 to 0.5 microgram/kg per min
Number of subjects: 23
Study 8684198 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine 2.5 to 10 micrograms/kg per min
Number of subjects: 23
Study 1653363 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (BRL 43694A) - single intravenous dose
Number of subjects: 152
Study 1653363 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone plus prochlorperazine
Number of subjects: 152
Study 6401422 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced substrate formula (40 kcal/kg/day, 1 to 1.5 g protein/kg/day, carbohydrate-nitrogen ratio 50:1)
Number of subjects: 22
Study 6401422 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% dextrose and 4.25% protein solution (50 kcal/kg/day, 1 to 1.5 g protein/kg/day, carbohydrate-nitrogen ratio 150:1)
Number of subjects: 22
Study 6401422 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonseptic patients receiving balanced substrate formula)
Number of subjects: 22
Study 6401422 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonseptic patients receiving 25% dextrose and 4.25% protein solution)
Number of subjects: 22
Study 31659854 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 32
Study 31659854 — intervention group
Group type: COMPARATOR
Intervention: Wakeful state
Number of subjects: 32
Study 28688174 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mL of tomato juice (TJ)
Number of subjects: 28
Study 28688174 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mL of tomato juice (TJ)
Number of subjects: 28
Study 28688174 — intervention group
Group type: COMPARATOR
Intervention: Water (Control)
Number of subjects: 28
Study 25820048 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (6 educational sessions)
Number of subjects: 1000
Study 25820048 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-interventional schools)
Number of subjects: 1000
Study 23886261 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE combined with sorafenib (T + S group)
Number of subjects: 79
Study 23886261 — intervention group
Group type: COMPARATOR
Intervention: TACE alone (T group)
Number of subjects: 79
Study 23886261 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib alone (S group)
Number of subjects: 79
Study 23886261 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE combined with sorafenib (T + S group) and Sorafenib alone (S group)
Number of subjects: 79
Study 23886261 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE combined with sorafenib (T + S group) and TACE alone (T group)
Number of subjects: 79
Study 21236730 — intervention group
Group type: EXPERIMENTAL
Intervention: Parotid-sparing IMRT
Number of subjects: 94
Study 21236730 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy
Number of subjects: 94
Study 19520595 — intervention group
Group type: EXPERIMENTAL
Intervention: RAPID‐3
Number of subjects: 128
Study 19520595 — intervention group
Group type: EXPERIMENTAL
Intervention: RADAI‐5
Number of subjects: 128
Study 19520595 — intervention group
Group type: EXPERIMENTAL
Intervention: DAS28‐ESR
Number of subjects: 128
Study 19520595 — intervention group
Group type: EXPERIMENTAL
Intervention: CDAI
Number of subjects: 128
Study 17544491 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine 15 mg/70 kg
Number of subjects: 10
Study 17544491 — intervention group
Group type: COMPARATOR
Intervention: d-amphetamine 0 mg (placebo)
Number of subjects: 10
Study 17544491 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine 3.125 mg/70 kg
Number of subjects: 10
Study 17544491 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine 7.5 mg/70 kg
Number of subjects: 10
Study 17544491 — intervention group
Group type: EXPERIMENTAL
Intervention: sublingual estradiol 0.25 mg
Number of subjects: 10
Study 15460844 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide-5-mononitrate
Number of subjects: 18
Study 15460844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 11008994 — intervention group
Group type: EXPERIMENTAL
Intervention: CPR-video protocol
Number of subjects: 335
Study 11008994 — intervention group
Group type: COMPARATOR
Intervention: CPR-social support intervention
Number of subjects: 335
Study 11008994 — intervention group
Group type: COMPARATOR
Intervention: CPR-instructor protocols
Number of subjects: 335
Study 8774514 — intervention group
Group type: COMPARATOR
Intervention: Exosurf
Number of subjects: 1126
Study 8774514 — intervention group
Group type: EXPERIMENTAL
Intervention: Infasurf
Number of subjects: 1126
Study 1502481 — intervention group
Group type: EXPERIMENTAL
Intervention: Baker's yeast capsules
Number of subjects: 19
Study 1502481 — intervention group
Group type: COMPARATOR
Intervention: Yeast exclusion (no dietary yeast)
Number of subjects: 19
Study 1502481 — intervention group
Group type: COMPARATOR
Intervention: Baseline (usual diet)
Number of subjects: 19
Study 6380447 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone hydrochloride (100 mg)
Number of subjects: 8
Study 6380447 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine hydrochloride (2 mg/kg)
Number of subjects: 8
Study 6380447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31372970 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision making (SDM) using routine outcome monitoring (ROM) in a national trial
Number of subjects: 0
Study 31372970 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision making (SDM) during the intake in a regional trial
Number of subjects: 0
Study 31372970 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine outcome monitoring (ROM) in clinical practice
Number of subjects: 0
Study 29515256 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil/folinic acid (5FU/FA)
Number of subjects: 238
Study 29515256 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine
Number of subjects: 238
Study 29515256 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil/folinic acid (5FU/FA) with low hENT1 expression
Number of subjects: 238
Study 29515256 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine with low hENT1 expression
Number of subjects: 238
Study 1358496 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 microgram/kg
Number of subjects: 6
Study 1358496 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1.0 microgram/kg
Number of subjects: 6
Study 1358496 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1.5 microgram/kg
Number of subjects: 6
Study 1358496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 22694757 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasudil
Number of subjects: 0
Study 20555311 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (100 mg/day for 7 days)
Number of subjects: 0
Study 20555311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18691985 — intervention group
Group type: EXPERIMENTAL
Intervention: epinastine
Number of subjects: 40
Study 18691985 — intervention group
Group type: EXPERIMENTAL
Intervention: ketotifen
Number of subjects: 40
Study 18691985 — intervention group
Group type: COMPARATOR
Intervention: azelastine
Number of subjects: 40
Study 15914352 — intervention group
Group type: EXPERIMENTAL
Intervention: Meconium-stained amniotic fluid (MSAF)
Number of subjects: 30
Study 15914352 — intervention group
Group type: COMPARATOR
Intervention: No meconium-stained amniotic fluid (non-MSAF)
Number of subjects: 30
Study 12887344 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP/BPBM/GTR (experimental group)
Number of subjects: 52
Study 12887344 — intervention group
Group type: COMPARATOR
Intervention: Open flap debridement (control group)
Number of subjects: 52
Study 10381285 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-carotene
Number of subjects: 74
Study 10381285 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma-tocopherol
Number of subjects: 74
Study 10381285 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene
Number of subjects: 74
Study 10381285 — intervention group
Group type: COMPARATOR
Intervention: Alpha-tocopherol
Number of subjects: 74
Study 10381285 — intervention group
Group type: COMPARATOR
Intervention: Ubiquinol-10
Number of subjects: 74
Study 8873009 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymosin alpha 1 (900 micrograms/m2 of body surface area twice weekly)
Number of subjects: 19
Study 8873009 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 8873009 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymosin alpha 1
Number of subjects: 19
Study 1793242 — intervention group
Group type: EXPERIMENTAL
Intervention: gentamicin
Number of subjects: 5
Study 1793242 — intervention group
Group type: EXPERIMENTAL
Intervention: neomycin
Number of subjects: 5
Study 1793242 — intervention group
Group type: EXPERIMENTAL
Intervention: silver sulfadiazine
Number of subjects: 5
Study 1793242 — intervention group
Group type: EXPERIMENTAL
Intervention: mupirocin
Number of subjects: 5
Study 1793242 — intervention group
Group type: COMPARATOR
Intervention: Omiderm (control)
Number of subjects: 5
Study 6732217 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg of Sch 29,482 orally every 6 h for 4 days
Number of subjects: 58
Study 6732217 — intervention group
Group type: COMPARATOR
Intervention: Placebo orally every 6 h for 4 days
Number of subjects: 58
Study 30669897 — intervention group
Group type: EXPERIMENTAL
Intervention: Early palmar plating (surgery)
Number of subjects: 80
Study 30669897 — intervention group
Group type: COMPARATOR
Intervention: Initial nonoperative treatment
Number of subjects: 80
Study 30669897 — intervention group
Group type: COMPARATOR
Intervention: Delayed surgery (for secondary displacement)
Number of subjects: 80
Study 28768446 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus 175/75 mg
Number of subjects: 89
Study 28768446 — intervention group
Group type: COMPARATOR
Intervention: Temsirolimus 75 mg
Number of subjects: 89
Study 26632632 — intervention group
Group type: EXPERIMENTAL
Intervention: Local infiltration anaesthetic (LIA)
Number of subjects: 50
Study 26632632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 24633171 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentle, non-pain-based language
Number of subjects: 0
Study 24633171 — intervention group
Group type: COMPARATOR
Intervention: Standard language
Number of subjects: 0
Study 21940133 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartSaver Sticker (n=26)
Number of subjects: 51
Study 21940133 — intervention group
Group type: COMPARATOR
Intervention: No HeartSaver Sticker (n=25)
Number of subjects: 51
Study 19825908 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone extended-release 12 mg on days 1-6
Number of subjects: 0
Study 19825908 — intervention group
Group type: COMPARATOR
Intervention: Risperidone immediate-release 2 mg on day 1 and 4 mg on days 2-6
Number of subjects: 0
Study 18043445 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentavalent human-bovine (WC3) reassortant rotavirus vaccine
Number of subjects: 2070
Study 18043445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2070
Study 19957383 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced musculoskeletal ultrasonography (CE-MUS) with SonoVue
Number of subjects: 41
Study 19957383 — intervention group
Group type: EXPERIMENTAL
Intervention: Power Doppler sonography (PDS)
Number of subjects: 41
Study 19957383 — intervention group
Group type: COMPARATOR
Intervention: Contrast-enhanced magnetic resonance imaging (CE-MRI) with Magnevist
Number of subjects: 41
Study 19957383 — intervention group
Group type: COMPARATOR
Intervention: B-mode ultrasound (US)
Number of subjects: 41
Study 19957383 — intervention group
Group type: COMPARATOR
Intervention: MRI
Number of subjects: 41
Study 15466681 — intervention group
Group type: EXPERIMENTAL
Intervention: ImPACT intervention (1-session, videotape and discussion)
Number of subjects: 817
Study 15466681 — intervention group
Group type: EXPERIMENTAL
Intervention: ImPACT intervention (with boosters)
Number of subjects: 817
Study 15466681 — intervention group
Group type: COMPARATOR
Intervention: Focus on Kids (FOK)
Number of subjects: 817
Study 11762657 — intervention group
Group type: EXPERIMENTAL
Intervention: IUCD insertion immediately after abortion
Number of subjects: 0
Study 9263381 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorette chewing gum (ad libitum)
Number of subjects: 21
Study 9263381 — intervention group
Group type: COMPARATOR
Intervention: Placebo chewing gum
Number of subjects: 21
Study 8450527 — intervention group
Group type: EXPERIMENTAL
Intervention: active-atenolol
Number of subjects: 46
Study 8450527 — intervention group
Group type: COMPARATOR
Intervention: placebo-atenolol
Number of subjects: 46
Study 8450527 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine treated patients
Number of subjects: 46
Study 8450527 — intervention group
Group type: EXPERIMENTAL
Intervention: captopril treated patients
Number of subjects: 46
Study 3544744 — intervention group
Group type: EXPERIMENTAL
Intervention: Etretinate (10 mg capsule once a day)
Number of subjects: 157
Study 3544744 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 157
Study 11573626 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 75
Study 11573626 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 75
Study 11573626 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 75
Study 11573626 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 75
Study 11573626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 30922302 — intervention group
Group type: EXPERIMENTAL
Intervention: ICS continued group
Number of subjects: 1144
Study 30922302 — intervention group
Group type: COMPARATOR
Intervention: ICS withdrawal group
Number of subjects: 1144
Study 29465649 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 750 mg + miconazole 200 mg intravaginal suppositories for 5 consecutive nights each month for 12 months
Number of subjects: 234
Study 29465649 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 5 consecutive nights each month for 12 months
Number of subjects: 234
Study 29465649 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 234
Study 27595688 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD)
Number of subjects: 1116
Study 27595688 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy without ICD
Number of subjects: 1116
Study 24198342 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG-triggered electrical stimulation to the four muscle groups of the affected arm plus usual therapy five times a week for four weeks
Number of subjects: 33
Study 24198342 — intervention group
Group type: COMPARATOR
Intervention: Usual therapy only
Number of subjects: 33
Study 21933805 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaflet giving information about ovarian/cervical cancer
Number of subjects: 146
Study 21933805 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer experts
Number of subjects: 146
Study 19900131 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtotal hysterectomy (SH)
Number of subjects: 132
Study 19900131 — intervention group
Group type: COMPARATOR
Intervention: Total hysterectomy (TH)
Number of subjects: 132
Study 17905507 — intervention group
Group type: EXPERIMENTAL
Intervention: ExP-A with blot-drying
Number of subjects: 32
Study 17905507 — intervention group
Group type: EXPERIMENTAL
Intervention: ExP-E with short evaporation (2-3s)
Number of subjects: 32
Study 16154196 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreous pegaptanib (0.3 mg)
Number of subjects: 172
Study 16154196 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 172
Study 12190957 — intervention group
Group type: EXPERIMENTAL
Intervention: TUDCA (1000 mg)
Number of subjects: 8
Study 12190957 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA (750 mg)
Number of subjects: 8
Study 9930158 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost (0.005%) once a day starting 2 days before surgery until the fifth postoperative week and diclofenac eyedrops 4 times a day before surgery on the day of surgery and 3 times a day until the fifth postoperative week (Group A)
Number of subjects: 0
Study 9930158 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost (0.005%) once a day starting 2 days before surgery until the fifth postoperative week and fluorometholone eyedrops 4 times a day before surgery on the day of surgery and 3 times a day until the fifth postoperative week (Group B)
Number of subjects: 0
Study 9930158 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost placebo once a day starting 2 days before surgery until the fifth postoperative week and diclofenac eyedrops 4 times a day before surgery on the day of surgery and 3 times a day until the fifth postoperative week (Group C)
Number of subjects: 0
Study 9930158 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost placebo once a day starting 2 days before surgery until the fifth postoperative week and fluorometholone eyedrops 4 times a day before surgery on the day of surgery and 3 times a day until the fifth postoperative week (Group D)
Number of subjects: 0
Study 7561189 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposome-adjuvanted vaccine
Number of subjects: 49
Study 7561189 — intervention group
Group type: COMPARATOR
Intervention: Control subvirion vaccine
Number of subjects: 49
Study 2162930 — intervention group
Group type: EXPERIMENTAL
Intervention: Information-mapped text with postquestions
Number of subjects: 65
Study 2162930 — intervention group
Group type: EXPERIMENTAL
Intervention: Information-mapped text with postquestions and feedback
Number of subjects: 65
Study 2162930 — intervention group
Group type: COMPARATOR
Intervention: Information-mapped text alone
Number of subjects: 65
Study 2162930 — intervention group
Group type: EXPERIMENTAL
Intervention: Modules with postquestions or postquestions and feedback
Number of subjects: 65
Study 2162930 — intervention group
Group type: COMPARATOR
Intervention: Modules without postquestions or feedback
Number of subjects: 65
Study 2162930 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted recall scores for work time spent
Number of subjects: 65
Study 647263 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic diagnosis and medications
Number of subjects: 200
Study 647263 — intervention group
Group type: COMPARATOR
Intervention: No evidence of disease and no treatment
Number of subjects: 200
Study 31236938 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2E1 activity (measured by 6‐hydroxychlorzoxazone/chlorzoxazone ratio)
Number of subjects: 0
Study 31236938 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP3A activity (measured by omeprazole sulfone/omeprazole ratio)
Number of subjects: 0
Study 31236938 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2E1 activity
Number of subjects: 0
Study 31236938 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP3A activity
Number of subjects: 0
Study 29482801 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 17
Study 29482801 — intervention group
Group type: COMPARATOR
Intervention: Breathing through a filter (Control)
Number of subjects: 17
Study 27215528 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial stapled transanal rectal resection (part‐STARR) combined with Bresler procedure
Number of subjects: 60
Study 27215528 — intervention group
Group type: COMPARATOR
Intervention: STARR only
Number of subjects: 60
Study 25024396 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss in the first 6 months
Number of subjects: 1000
Study 25024396 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss from 0 to 2 years
Number of subjects: 1000
Study 25024396 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight cycling (0-6 times per participant)
Number of subjects: 1000
Study 25024396 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight cycling after adjustment for baseline weight
Number of subjects: 1000
Study 22319035 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (10 and 20 mg/d)
Number of subjects: 20
Study 22319035 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (60 and 120 mg/d)
Number of subjects: 20
Study 22319035 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen and Raloxifene
Number of subjects: 20
Study 20107465 — intervention group
Group type: EXPERIMENTAL
Intervention: PARADE intervention (multicomponent intervention with eight lesson plans, child-focused storybooks, and parent newsletters)
Number of subjects: 782
Study 20107465 — intervention group
Group type: EXPERIMENTAL
Intervention: PARADE intervention
Number of subjects: 782
Study 20107465 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 782
Study 17627809 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional radiotherapy (RT) or chemoradiotherapy (CRT)
Number of subjects: 884
Study 17627809 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumferential resection margin (CRM) involvement
Number of subjects: 884